|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the influence of polymorphisms of IL-28B rs12979860 and TBX21 rs17250932, rs4794067 as well as viral factors (HCV genotype, F protein) on the outcome of HCV infection, we genotyped 565 patients with chronic HCV infection, 191 patients spontaneously resolved from HCV infection, 359 healthy controls and 383 treatment-naïve CHC patients with pegylated interferon-α and ribavirin (PEG IFN-α/RBV).
|
29399747 |
2018 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
The impact of chronic hepatitis C (CHC) on bone mineral density (BMD) has been well studied in adults with a relative paucity of data in children, especially concerning effect of treatment with pegylated interferon (PEG-IFN) plus ribavirin (RV).
|
28130750 |
2017 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV).
|
27180197 |
2016 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively examined 541 patients affected by CHC who were treated with pegylated interferon (PEG-IFN) and ribavirin from 2003 to 2012.
|
26060059 |
2015 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To compare the role of IFNL4 polymorphism with the two commonly used IL28B SNPs rs12979860 and rs8099917 on response to PEG/RBV in patients with CHC.
|
24205831 |
2014 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy remains the standard of care for CHC genotype 1 in many Asian countries, and single nucleotide polymorphism or genotype of the interleukin-28B (IL28B) gene is associated with the development of sustained virologic response (SVR).
|
23829453 |
2014 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This 28-day, double-blind, randomized, placebo-controlled study evaluated once daily GSK2336805 60 mg alone or in combination with peginterferon alfa-2a (180 μg per week) and ribavirin (1000-1200 mg daily) (PEG/RIBA) in treatment-naive genotype 1 CHC subjects.
|
24107072 |
2014 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
A strong association between single nucleotide polymorphisms (SNPs) of IL28B and treatment outcomes of pegylated interferon-α (PEG IFNα) and ribavirin (RBV) has been shown in chronic hepatitis C (CHC) patients with genotype 1.
|
24102823 |
2014 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chronic hepatitis C (CHC) patients achieving rapid virological response (RVR) on PEG-IFN/ribavirin (P/R) therapy have high chance of sustained virological response (SVR).
|
23874444 |
2013 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the anti-hepatitis C virus (HCV) effect of statins in vitro and clinical efficacy of fluvastatin combined with Pegylated interferon (PEG-IFN)/ribavirin therapy for chronic hepatitis C (CHC) have been reported, the details of clinical presentation are largely unknown.
|
22989264 |
2013 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to investigate the relationship between methylation of SOCS-1 and sustained virologic response (SVR) in chronic hepatitis C (CHC) patients treated with pegylated interferon (PEG-IFN)-alpha and ribavirin (RBV).
|
23702664 |
2013 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
The standard treatment for patients with chronic hepatitis C (CHC), pegylated interferon-α (PEG-IFN) plus ribavirin (RBV) does not provide a sustained virological response (SVR) in all patients.
|
22713131 |
2012 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 36 studies involving 10912 cases with CHC receiving PEG-IFN-α plus ribavirin met the inclusion criteria.
|
22842190 |
2012 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotype 1 (G1) chronic hepatitis C (CHC) patients achieving a rapid virological response (RVR) on pegylated interferon (PEG-IFN) plus ribavirin have a high chance of sustained virological response (SVR), influenced by IL28B status, viral load, fibrosis and insulin resistance.
|
22505587 |
2012 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination therapy with PEG-IFN-α and RBV demonstrated good tolerability in CHC genotype 3 infection.
|
21706207 |
2011 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, pretreatment serum protein profiling by SELDI-TOF/MS is variable for identification of response-related host factors, which are useful for treatment efficacy prediction in CHC receiving PEG-IFN plus RBV.
|
20927485 |
2011 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attempt to create simple practical algorithm for prospective assessment of PEG interferon/ribavirin related treatment response in individuals with chronic hepatitis C (CHC) basing on the risk factors defined prior to the treatment initiation.
|
22130295 |
2011 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
A common genetic variation near the IL28B gene has been found to affect the response to PEG-IFN plus ribavirin therapy for CHC.
|
22156487 |
2011 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
In total, 126 consecutive chronic hepatitis C (CHC) patients who received combined PEG-IFN and RBV therapy were included.
|
19817959 |
2010 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of pegylated-interferon (PEG-IFN)/ribavirin is currently the standard of care antiviral treatment for chronic hepatitis C (CHC), but optimal results require an individual approach.
|
20594246 |
2010 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data concerning the efficacy of PEG-IFN alpha 2a plus ribavirin treatment in treatment-naive, genotype 4-infected chronic hepatitis C (CHC) patients from Europe are limited.
|
19413697 |
2009 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to elucidate impact of IR and beta-cell function on the response to peginterferon-alpha (PEG-IFN)/ribavirin combination therapy in chronic hepatitis C (CHC) patients.
|
19231011 |
2009 |
|
Pseudohyperkalemia Cardiff
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three hundred and twenty-one CHC patients including virologic nonresponders to combination IFN plus RBV (n = 219) or IFN monotherapy (n = 47), and relapsers to combination therapy (n = 55) were randomized to receive PEG IFN alpha-2b 1.5 microg/kg per wk plus RBV 800 mg per day (Regimen A, n = 160) or PEG IFN alpha-2b 1.0 microg/kg per wk plus RBV 1,000-1,200 mg per day (Regimen B, n = 161) for 48 wks.
|
16279900 |
2005 |